Consequences of anti-vascular endothelial growth factor treatment lapse in patients with retinal vein occlusion.

Jessica C LiuPeter AlsaloumAmogh I IyerPeter M KaiserRishi P Singh

Published in: Eye (London, England) (2022)

RVO patients with any lapse of anti-VEGF treatment are at risk for poorer anatomic and visual outcomes. Though BCVA normalizes upon treatment resumption, patients experience a statistically significant increase in CST that does not recover.

Keyphrases

vascular endothelial growth factor
end stage renal disease
chronic kidney disease
type diabetes
newly diagnosed
adipose tissue
insulin resistance
diabetic retinopathy
replacement therapy